YOBEL ASEFAW: Open Payments
NPI 1114624509 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,429 in 183 payments from 18 companies in 2025. Trend: 2023 $562 · 2024 $2,556 · 2025 $3,429
Food & beverage: $3,429
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 30 | $550 |
| Neurocrine BioSciences, Inc. | 20 | $416 |
| Alkermes, Inc. | 15 | $375 |
| Teva Pharmaceuticals USA, Inc. | 14 | $310 |
| ABBVIE INC. | 20 | $278 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 28 | $273 |
| E.R. Squibb & Sons, L.L.C. | 10 | $230 |
| Janssen Pharmaceuticals, Inc | 8 | $189 |
| Vanda Pharmaceuticals Inc. | 7 | $183 |
| Axsome Therapeutics, Inc. | 7 | $149 |
Products named: REXULTI, INGREZZA, ARISTADA, VRAYLAR, CAPLYTA, COBENFY, AUSTEDO XR, FANAPT.
Industry payments across NV — which companies pay providers there.
